Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — FY2025 Earnings Presentation
19 slides from Zim Laboratories's earnings presentation, 2025
Slide 1: Zim Laboratories Limited Q4 & FY25 Earnings Presentation
ZIM LABORATORIES LIMITED Q4 & FY25 – EARNINGS PRESENTATION
Slide 2: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 3: Content
CONTENT 01 EXECUTIVE SUMMARY – FY25 02 FINANCIAL HIGHLIGHTS 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 4: Executive Summary – FY25
EXECUTIVE SUMMARY – FY25 o Total Operating Income grew to ₹3,790 Mn (↑3.2% YoY), driven by sustained export momentum and high-value innovative product contributions Business Performance o Export revenue stood at ₹3,125 Mn (↑8.9% YoY), contributing 82% to the TOI o EBITDA increased to ₹495 Mn, with m
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS FY25 Q4 FY25 Total Operating Income at ₹3,790 Total Operating Income at ₹1,087 Mn, reflecting an 3.2% YoY growth 3,790 Mn 1,087 Mn Mn, reflecting a 12.9% QoQ from ₹3,674 Mn in FY24 growth EBITDA at ₹163 Mn, up 22% from Q3; EBITDA is at ₹495 Mn, up 6.4% YoY EBITDA margins improve
Slide 6: Strategic & Execution Updates
STRATEGIC & EXECUTION UPDATES Innovative Products (NIP + OTF) Product Filings & Development o NIP and OTF operating income o In FY25, we completed 23 NIP (6 reached ₹624 Mn in FY25, marking a molecules), 17 OTF (5 molecules), and 10 68% YoY growth FF (5 molecules) filings, including 5 NIP (4 o This
Slide 7: Financial Performance – FY25
FINANCIAL PERFORMANCE – FY25 Total Operating Income EBITDA & EBITDA margin 12.7% 13.1% o Total Operating Income grew 3.2% YoY, driven by contributions from our Innovative Product basket (NIP + OTF) ; we faced headwinds 3,790 such as political instability and currency 495 3,674 465 issues resurging i
Slide 8: Financial Performance – Q4FY25
FINANCIAL PERFORMANCE – Q4FY25 Total Operating Income EBITDA & EBITDA margin Profit After Tax (PAT) & PAT margin 14.6 % 13.8 % 15% 6.9 % 4.2 % 4.5% 1,179 1,087 172 163 81 963 133 49 40 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Total Operating Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ M
Slide 9: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 33% 83% 82% 77% 29% 74% 71% 26% 67% 23% 17% 18% 255 266 268 978 224 891 201 196 708 739 654 552 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q3FY24 Q4FY24 Q1
Slide 10: Revenue Mix
REVENUE MIX Q4FY24 Q4FY25 FY24 FY25 25, 2% 158, 4% 32, 3% 646, 18% 130, 3% 178, 16% 536, 14% 185, 16% 2,870, 3,125, 969, 82% 878, 81% 78% 83% Numbers in ₹Mn Export India Deemed Export o FY25: Revenue from exports increased 8.9% YoY to ₹3,125 Mn, compared to ₹2,870 Mn in FY24 o Growth in Exports was
Slide 11: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 21.8% 17.8% 14.0% 13.5% 12.7% 178 164 10.3% 147 9.5% 8.5% 135 109 112 82 70 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 ₹ 372 Mn, in FY24 ₹ 624 Mn in FY25; Up 68% YoY o FY25: NIP + OTF
Slide 12: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Product 1 Urology Product 2 Gastrointestinal Product 3 Anti – Coagulant Di-Methyl Fumarate CNS Product 5 Uro
Slide 13: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Rizatriptan CNS Sildenafil Erectile Dysfunction Product 3 CNS Product 4 Erectile Dysfunction Buprenorphine O
Slide 14: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 90 2 76 29% 31% Capital Expenses on BE study, R&D Team Post- 9.7% PhDs registrations etc Size Graduates 4% 16% 8.8% Capital Expenses on Infrastructure & Equipment 7 4 ₹333
Slide 15: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q4FY25 Q4FY24 YoY% Q3FY25 QoQ% FY25 FY24 YoY% Total Operating Income 1,087 1,179 (7.7%) 963 12.9% 3,790 3,674 3.2% Other Income 17 15 10.7% 18 (5.6%) 58 52 13% Total Income 1,104 1.194 (7.5%) 981 12.6% 3,848 3,725 3.3% EBITDA 163 172 (5.2%) 133 22.5% 495 465 6.4%
Slide 16: Balance Sheet
BALANCE SHEET Particulars (₹ Mn) FY25 FY24 FY23 FY22 Gross Block – Tangible & Intangible Assets 3,453 3,089 2,257 1,920 including WIP Net Block – Tangible & Intangible Assets 2,347 2,031 1,357 1,174 including WIP Other Non- Current Assets 60 161 150 121 Current Assets 2,313 2,276 1,909 2,121 Total A
Slide 17: Key Financials
KEY FINANCIALS Gross & Net Fixed Assets (₹ Mn) Gross Current Assets (₹ Mn) & % of Total Assets 62% 3,453 56% 3,089 51% 49% 2,257 2,347 1,920 2,031 1,174 1,357 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Gross Fixed Assets Net Fixed Assets Net Worth (₹ Mn) Total Borrowing (₹ Mn) & Gearing % 2,387 2,522 4
Slide 18: Shareholding
SHAREHOLDING Ownership % (March 2025) Traded Volume (In K) BSE+NSE 30,000 26,593 5% 25,000 20,000 33% 18,435 15,000 14,093 14,104 13,089 11,313 42% 10,000 5,000 12% 0 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 8% Promoter HNI Body Corporates Other Public Shareholding • Number of Shareholders in Q4FY2
Slide 19: Thank You
THANK YOU INVESTOR RELATIONS ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@goindiaadvisors.com priya@goindiaadvisors.com M:+91 9769364166 M:+91 84510295